Sponsor content
62 result(s) found, displaying 11 to 20
-
Australian Public Assessment Report (AusPAR)IQIRVO (elafibranor) is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.
-
Australian Public Assessment Report (AusPAR)RELFYDESS (relabotulinumtoxinA) is for the temporary improvement in the appearance of moderate to severe glabellar lines at maximum frown and of moderate to severe lateral canthal lines seen at maximum smile.
-
Australian Public Assessment Report (AusPAR)BYLVAY (odevixibat) is for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older.
-
Prescription medicine registrationActive ingredients: cabozantinib (S)-malate.
-
Prescription medicine registrationActive ingredients: odevixibat, odevixibat sesquihydrate.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RELFYDESS relabotulinumtoxinA 100 units/mL solution for injection vial.
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SOHONOS palovarotene 5 mg capsule blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SOHONOS palovarotene 1.5 mg capsule blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SOHONOS palovarotene 1 mg capsule blister pack.